TRAF6, a key signaling molecule in the canonical NFκB pathway, exhibited a significant downregulation with a fold change of 0.35 in UC patients as compared to non-IBD controls (p = 0.03) showing an inverse relation with the miR-125b expression. Here, TRAF6 is linked to inflammatory bowel disease.